A proposed $4.5 million settlement resolves a class action alleging that certain Robitussin over‑the‑counter cough medicines containing dextromethorphan (DXM) were deceptively marketed as “Non‑Drowsy.” Plaintiffs say the labeling misled buyers about the likelihood of drowsiness; Haleon and GSK deny wrongdoing but agreed to the settlement to avoid further litigation. Consumers who purchased specified Robitussin products in the U.S. between February 16, 2016 and January 21, 2025 may be eligible for roughly $1.50–$4.75 per claim (one claim per household without proof, up to three with receipts), with a claim deadline of May 12, 2025. The case matters because it highlights how OTC drug makers are accountable not only to FDA labeling standards but also to truth‑in‑advertising rules enforced by the Federal Trade Commission and state consumer protection laws; class actions like this can prompt changes in marketing, warnings, or packaging even when manufacturers contest liability. Allegations over “non‑drowsy,” “natural,” or other consumer‑friendly claims are increasingly common in the supplement and OTC drug space, and settlements can encourage companies to scrutinize clinical evidence and advertising practices more closely to avoid regulatory scrutiny and similar lawsuits.